Regulatory policy

Asembia 2022 Summit to address biosimilar uptake and policy implications for specialty pharmacy

Many topics will be discussed at this year’s Asembia Specialty Pharmacy Summit, which will be held in person in Las Vegas May 2-5, including updates on cell and gene therapies and information on the future of industry.

Asembia’s 2022 Specialty Pharmacy Summit is scheduled to take place next week May 2-5 in Las Vegas, Nevada, and will feature keynote speaker Scott Gottlieb, MD, former FDA commissioner and senior advisor to CMS.

Sessions and panels will include discussions on all things specialty pharmacy, including treatment advances, market access strategies, and the pharmaceutical pipeline.

The organization’s last meeting was in October 2021, postponed due to COVID-19, while next week’s meeting will see a return to the regular spring timeslot.

Continuing education courses cover the full range of treatments for disease states, including opportunities to learn how to manage atopic dermatitis in pediatric patients and an exam for pharmacists specializing in the management of idiopathic pulmonary fibrosis.

Featured sessions also include updates on popular topics such as the role of pharmacists in driving future adoption of biosimilars and the importance of protecting patient data alongside national data security risks.

Policy discussions will focus on the challenges of navigating state regulations, an overview of President Biden’s health agenda in an election year, and the 30th anniversary passage of the Public Health Service’s 340B program ( PHS).

On the payer side, experts are expected to discuss the slow adoption of digital therapies while representatives from Amazon Pharmacy and Eli Lilly will present a session titled “Bringing Ecommerce Insights to Pharmacy.”

Updates on cell and gene therapies will be provided as well as legal considerations on specialty pharmacies engaging in different patient infusion models.

The agenda includes several patient-centric discussions, including one on overcoming the social determinants of health through specialist teams, presented by representatives from Walgreens.

An additional session titled “Navigating the Pandemic with EUA Therapies” will address issues raised by supply challenges, therapeutic indications and time constraints, while “Understanding the use of patient-reported outcomes to improve Pharmaceutical Care” will highlight CVS’s efforts to optimize its supply management practices through personalized digital engagement.

Pharmacy accreditation, changes in care sites and value-based contracts will also be covered, along with information on medication adherence and financial barriers that can lead to discontinuing prescriptions.

The conference will take place at the Wynn Hotel & Encore with over 5,000 industry attendees expected at the in-person event.

Keep an eye on our Asembia conference page for live coverage from Las Vegas, starting May 2.